Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Saghmos Therapeutics, Inc. Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study April 17, 2024 From Saghmos Therapeutics, Inc. Via Business Wire Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516 March 12, 2024 From Saghmos Therapeutics, Inc. Via Business Wire Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer February 21, 2024 From Saghmos Therapeutics, Inc. Via Business Wire Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516 February 07, 2024 From Saghmos Therapeutics, Inc. Via Business Wire Saghmos Therapeutics Announces Appointment of Pharmaceutical Industry Veteran Fred Hassan as Chairman of the Board of Directors October 03, 2023 From Saghmos Therapeutics, Inc. Via Business Wire Saghmos Therapeutics Announces Issuance of US Patent for ST-62516 for the Reduction of Kidney Injury in Patients with Chronic Kidney Disease Undergoing Contrast Procedures November 17, 2021 From Saghmos Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.